MERCURI-2 – Dapagliflozin and AKI Post Cardiac Surgery
Dapagliflozin and Acute Kidney Injury Following Cardiac Surgery
A Randomized Clinical Trial
Oosterom-Eijmael et al. JAMA. 2026;336(9):765-773. doi:10.1001/jama.2026.9268
Clinical Question
- In adults undergoing elective cardiac surgery, does peri-operative dapagliflozin, initiated the day before surgery, compared with placebo, reduce acute kidney injury (AKI) within 7 post-operative days?
Background
- AKI occurs in up to 50% of patients undergoing cardiac surgery and is associated with short and long term morbidity and mortality
- The pathophysiology of AKI post cardiac surgery is complex. Hypoperfusion, hypoxia, oxidative stress, bypass-induced inflammation and reperfusion injury have all been implicated
- Sodium-glucose cotransporter 2 (SGLT2) inhibitors reduce the progression of chronic kidney disease (CKD), in addition to their initial purpose as an oral anti-hyperglycaemic
- There is growing interest in the potential of SGLT2 inhibitors to protect against AKI due to decreased glomerular pressure, glomerular filtration rate, renal metabolic requirements
- Post-hoc analysis and meta-analyses of pivotal SGLT-2 inhibitor trials have suggested substantial AKI risk reduction with these medications
- A previous single centre open-label RCT biomarker study published by the same group demonstrated a marked decrease in AKI for patients randomised to receive empagliflozin (another SGLT-2 inhibitor) prior to cardiac surgery (20 % vs 66.7 %; absolute difference 46.7 %, 95 % CI, −69.7 – -23.6; P < .001)
- A single centre open-label RCT in Brazil found lower rates of AKI 22.5% of the empagliflozin group vs. 39.1% in the control group (relative risk [RR] 0.57 [95% CI 0.34-0.96]; P = 0.03) for patients receiving empagliflozin for 3 months prior to cardiac surgery, which was withheld 72 hours prior to the operation
- Most current guidance prior to the publication of this trial suggested withholding SGLT2 inhibitors for 72 hours prior to major surgery due to the risk of euglycaemic ketoacidosis and unwanted diuresis
Design
- Investigator initiated, multicentre, double-blind, placebo-controlled RCT
- Double-blind randomisation in permuted, variable blocks, stratified by gender, presence of type 2 diabetes and study site
- Primary statistical analysis on an intention-to-treat basis
- Primary outcome
- Incidence of AKI up to 7 days post cardiac surgery as defined by KDIGO criteria
- an increase in serum creatinine level of 0.3 mg/dL
(26.5 μmol/L) or greater within 48 hours or, - 1.5-fold or greater increase in creatinine level within 7 days of surgery or,
- Urine output less than 0.5 mL/kg/h for 6 to 12 hours after surgery
- an increase in serum creatinine level of 0.3 mg/dL
- Baseline creatinine was typically that taken on hospital admission the day before surgery
- Incidence of AKI up to 7 days post cardiac surgery as defined by KDIGO criteria
- Sample size calculation: 784 patients would be required to detect an absolute risk reduction of 7.9% in the primary outcome from a baseline of 22% and a fasle negative rate of 5%
Setting
- 7 hospitals in the Netherlands
- Enrolment June 8 2023 – January 27 2025. Follow up until May 16 2025
Population
- Inclusion: >18 years old, scheduled for elective cardiac surgery
- Exclusion:
- Type 1 diabetes
- Type 2 diabetes with BMI <25 kg/m^2 using multiple daily insulin injections
- Baseline eGFR <20mL/min/1.73m^2
- History of diabetic ketoacidosis
- Systolic blood pressure <100mmHg at time of enrolment
- Current treatment with SGLT2 inhibitors
- Known or suspected allergy to SGLT2
- Pregnant and breastfeeding women
- Women with childbearing potential who were not using “adequate” contraceptive methods
- 784 patients randomised out of 2551 screened
- 392 in dapagliflozin group, 87% of whom received all 4 doses of dapagliflozin
- Very well matched groups post randomisation
- Median age 68
- 76% male
- 97% white
- 12% type 2 DM
- Similar distribution of comorbidities, functional status, pre-operative medications, pre-operative renal function, type and duration of surgery and cardio-pulmonary bypass
Intervention
- Dapagliflozin
- 10mg daily for 4 doses
- First dose given evening before surgery, second dose morning of surgery, then on post-op day 1 and 2
- Original dapagliflozin tablets were re-encapsulated to prevent unblinding
Control
- Placebo
- Visually identical placebo containing microcrystaline cellulose
- 4 doses given at same schedule as intervention
Management common to both groups
- All other aspects of pre, intra and post-operative care were at clinician discretion
Outcome
- Primary outcome:
- Dapagliflozin group had a significant reduced rate of AKI
- 28% vs 52%, risk difference, −24% [95% CI, −31% to −17%]; relative risk [RR], 0.54 [95% CI, 0.45-0.65]; P < .001
- Post-hoc analysis demonstrated that this result was driven by AKI defined by urine output criteria
-
- When AKI was defined by creatinine alone, rates were similar (14% in dapagliflozin group, 15% in control)
-
- Dapagliflozin group had a significant reduced rate of AKI
- Secondary outcomes:
- Significantly greater in the dapagliflozin group
- Postoperative maximum change in eGFR vs baseline
- -7.4 vs −1.8mL/min/1.73 m2 , between-group difference median 4.4 (3.0 to 5.8), P <0.001
- Postoperative maximum change in eGFR vs baseline
- No difference between groups
- Low rates of Stage 3 AKI (<1% in both groups)
- De novo atrial fibrillation
- MACE 30
- MAKE 30
- Hospital length of stay
- Significantly greater in the dapagliflozin group
- Safety outcomes
- Low rates of mycotic infections in both groups
- 1 case of ketoacidosis in dapagliflozin group, none in control
- Similar rates of reoperation and AF
Authors’ Conclusions
- “In patients undergoing elective cardiac surgery, 4 doses of dapagliflozin, beginning the day before surgery, reduced the incidence of AKI during the 7-day postoperative period”
Strengths
- Well conducted, multicentre double blinded RCT
- Good follow up, of 800 patients randomised 784 included in primary analysis
- Intervention could be readily and cheaply implemented into clinical practice
- Large effect size demonstrated which holds up in both intention to treat and per-protocol analyses
Weaknesses
- Despite a large effect size (24% reduction in AKI), this was entirely driven by urine output criteria (<0.5mL/kg/hr for 6-12 hours)
- Although the KDIGO definition of AKI is widely used and well validated, here it led to a large reported effect size with no difference in any patient centered outcome
- The authors argue that SGLT2 inhibitors have not been shown to have significant diuretic effect, but cite evidence in stable, euvolaemic outpatients which may not be applicable to a cardiac-surgical population
- Low rates of severe renal injury (grade 3 AKI, MAKE-30)
- Noting a wide range of exclusion criteria, a trial in an enriched population would be informative but may increase odds of adverse outcomes
- Homogenous population (97% white, 75% male) may decrease generalisability
- No statistical adjustment for multiplicity of outcomes
- Data that would be important to the ICU clinician including healthcare costs, perioperative glucose measurements, haemodynamic data and post-operative cardiac function were available to the authors but not analysed
The Bottom Line
- MERCURI-2 demonstrates that peri-operative dapagliflozin reduces KDIGO-defined post-op-AKI, an effect almost entirely driven by fewer patients meeting the urine output criterion, without reducing creatinine-defined AKI or demonstrating a patient centred benefit
- I will not routinely give SGLT2 inhibitors to my cardiac surgical patients based on these results but eagerly await further data, ideally in an higher risk population, to guide practice
External Links
Metadata
Summary author: Daniel Chung
Summary date: 01/10/2026
Peer-review editor: David Slessor
Picture by: pexels.com | Zelch Csaba



